Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: Preliminary report

International Journal of Clinical Oncology

Volumn 9, Issue 2, 2004, Pages 125-129

  Hoshi, Senji ^a   Ohyama, Chikara ^b   Ono, Kunio ^a   Takeda, Atsushi ^c   Yamashita, Shinichi ^c   Yamato, Takashi ^c   Itoh, Akihiro ^c   Satoh, Makoto ^c   Saito, Seiichi ^c   Okada, Yasuhiro ^d   Sohma, Fumihiko ^e   Arai, Yoichi ^c  

^a Division of Cancer Control   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Kesennuma County Hospital   (Japan)

^e Hachinohe City Hospital   (Japan)

Author keywords

Docetaxel; Gemcitabine; Metastatic urothelial cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; PLATINUM;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALE; METASTASIS; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; TAXOIDS; TREATMENT OUTCOME; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 2442559185     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-003-0379-8     Document Type: Article

References (20)

1. Hertel LW, Boder GB, Kroin JS, et al. (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422
2. Lorusso V, Pollera CF, Antimi M, et al. (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208-1212
3. Stadler WM, Kuzel T, Roth B, et al. (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398
4. Vaishampayan U, Parchment RE, Jasti BR, et al. (1999) Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54 (Suppl 6A):22-29
5. Haldar S, Basu A, Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233
6. Sternberg CN, Yagoda A, Scher HI, et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448-2458
7. Bellmunt J, Guillem V, Paz-Ares L, et al. (2000) Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer 36 (Suppl 2):17-25
8. Kuroda M, Kotake T, Akaza H, et al. (1998) Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Jpn J Clin Oncol 28:497-501
9. Bajorin DF, McCaffrey JA, Dodd PM, et al. (2000) Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 88:1671-1678
10. Lorusso V, Manzione L, De Vita F, et al. (2000) Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164:53-56
11. Pectasides D, Glotsos J, Bountouroglou N, et al. (2002) Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 13:243-250
12. Hussain M, Vaishampayan U, Du W, et al. (2001) Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19:2527-2533
13. World Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO, Geneva
14. Cook AM, Huddart RA, Jay G, et al. (2000) The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer 82:1952-1957
15. Tannock I, Gospodarowicz M, Connolly J, et al. (1989) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 142:289-292
16. Dimopoulos MA, Finn L, Logothetis CJ (1994) Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 151:598-600
17. Pollera CF, Ceribelli A, Crecco M, et al. (1994) Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5:182-184
18. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al. (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (Suppl 11):72-79
19. von der Maase H, Hansen SW, Roberts JT, et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068-3077
20. Stadler WM (2002) Gemcitabine doublets in advanced urothelial cancer. Semin Oncol 29 (Suppl 3):15-19